The Claim
In adults with type 2 diabetes, IDegLira reduces postprandial glucose increments across breakfast, lunch, and dinner more than insulin degludec alone and to a similar extent as liraglutide alone, as measured by continuous glucose monitoring over 72 hours.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, the combination drug IDegLira lowers blood sugar spikes after breakfast, lunch, and dinner more than insulin degludec alone and as much as liraglutide alone, based on continuous glucose monitoring over three days.
See the scientific wording
In adults with type 2 diabetes, IDegLira reduces postprandial glucose increments across all three main meals (breakfast, lunch, dinner) more than insulin degludec alone, with similar effects to liraglutide alone, as demonstrated by continuous glucose monitoring over 72 hours.
A hormone-like compound binds to receptors on the pancreas, causing insulin-producing cells to release more insulin when blood sugar rises after eating, while simultaneously telling sugar-releasing cells to stop releasing sugar. This dual action lowers the spike in blood sugar after meals.
What the research says
1 studyIDegLira, a combo pill with insulin and a diabetes hormone, lowers blood sugar spikes after meals better than insulin alone and just as well as the hormone alone — proven by tracking blood sugar for three days in people with type 2 diabetes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.